Core Viewpoint - The current revenue share from AI business for Rongke Technology is low, attributed to industry development patterns and the company's product R&D and market advancement pace, rather than a significant shortfall in commercialization capability [2] Group 1: AI Business Development - The AI business is still in the strategic investment and market expansion phase, with a product matrix that includes AI medical record quality control, severe illness intelligent agents, and DRG/DIP medical insurance cost control systems [2] - The company plans to continue increasing R&D investment in AI and leverage its existing customer base in medical institutions to accelerate business scale expansion [2]